Masimo and Newborn Foundation Jointly Announce Mobile Health Initiative to Reduce Global Newborn Mortality
Masimo today announced the launch of iSpO2 Rx Pulse Oximeter with M-LNCS connector, enabling adhesive sensor use on newborns for accurate and cost-effective screening with mobile devices in low-resource settings. iSpO2 Rx features Masimo SET® technology -- shown through studies to be the most accurate pulse oximetry during challenging conditions and proven to help clinicians identify life-threatening conditions in newborns. iSpO2 Rx, available outside the U.S., provides accurate oxygen saturation (SpO2), pulse rate (PR), and perfusion index (PI) results from an iPhone, iPad, and iPod touch, and soon on select mobile devices for Android.
iSpO2 Rx, announced ahead of the mHealth Summit in Washington, D.C., Dec. 8-11, is the lynchpin of an ongoing collaboration with the Newborn Foundation, and marks the debut of the BORN Project -- Birth Oximetry Routine for Newborns -- the first global health initiative to reduce infant mortality through earlier detection of illness, disease and congenital birth defects through access to mobile-enabled technology that measures blood-oxygen levels in newborns. Until now, available pulse oximeters in low-resource settings have been inaccurate, lacked the ability to use adhesive sensors required for screening newborns, and were unable to simply and wirelessly transfer test results.
Globally, about 3.3 million newborns die within the first month of life, with neonatal infection, sepsis, pneumonia and birth defects among the major killers, according to the World Health Organization. The BORN Project was developed to help reduce neonatal mortality, a critical Millennium Development Goal, by deploying accessible and effective mobile technology targeting early detection of several of the major causes of newborn death. Clinical studies have shown that pulse oximetry screening can help detect conditions such as pneumonia, early-onset sepsis, neonatal infection and pulmonary hypertension,1 in addition to congenital heart defects.
"This simple, noninvasive check of oxygen levels in newborns is among the most effective health measures that can be deployed to reduce newborn mortality," said Annamarie Saarinen, co-founder and chairman of the Newborn Foundation. "We just saw how valuable this is, firsthand, while in the Philippines during Typhoon Haiyan. The mHealth Summit marks a historic opportunity to share this initiative and new technology that is finally available to babies in low-resource healthcare environments through mHealth innovation. We're very excited to be partnering with Masimo and public health to deploy this technology and advance its use as part of routine newborn care."
"From a public health perspective, neonatal infection, sepsis and pneumonia can all be treated more effectively if the conditions are detected early," said Darshak Sanghavi, MD, fellow and managing director, Engelberg Center for Health Care Reform at the Brookings Institution and associate professor of pediatrics at the University of Massachusetts Medical School. "Incorporating routine pulse oximetry as a universal 'vital sign' in newborns could be an important global life-saving tool."
"Through the BORN Project, Masimo is eager to help clinicians -- especially those working in low-resource areas of the world -- gain access to Masimo SET iSpO2 Rx as the most effective, affordable pulse oximeter that is accurate in challenging conditions of patient movement and low perfusion to help save the lives of newborns," said Masimo founder and CEO Joe Kiani.
More about iSpO2
RxiSpO2 Rx utilizes the same Masimo SET® Measure-through Motion and Low Perfusion pulse oximetry technology proven by more than 100 independent and objective studies and used on more than 100 million patients a year in leading hospitals worldwide, including eight of the top 10 on the U.S. News & World Report Best Hospitals Honor Roll (2013-2014). Compared to other pulse oximeters, Masimo SET® provides measurements specifically validated during patient motion and low perfusion, both common in newborns. Moreover, Masimo SET® pulse oximetry has been shown to help clinicians reduce retinopathy of prematurity (ROP)2 in neonates, and effectively screen newborns for congenital heart disease.3,4
iSpO2 Rx also features a downloadable and upgradeable iSpO2 Rx App, ensuring clinicians have the latest telemedicine technologies at their fingertips at all times. iSpO2 Rx can store and email up to 12 hours of measurement history in a global standard .CSV file format. iSpO2 Rx with the M-LNCS connector are compatible with Masimo adhesive and reusable sensors, and are uniquely designed to offer the best pulse oximetry performance for use in neonatal, infant, pediatric, and adult patients.
iPad, iPhone, and iPod touch are trademarks of Apple Inc., registered in the U.S. and other countries.
1 Ewer A. Review of pulse oximetry screening for critical congenital heart defects in newborn infants. Curr Opin Cardiol 2013;28:92-6.
2 Castillo A, et al. Acta Paediatr. 2011 Feb.;100(2):188-92.
3 de-Wahl Granelli A., et al. BMJ. 2009 Jan 8;338.
4 Ewer A, et al. Health Technol Assess. 2012;16(2):1-184.